Skip to main content

Advertisement

SpringerLink
Log in

Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Antibiotics for presumed small intestinal bacterial overgrowth have been shown to improve irritable bowel syndrome symptoms in at least 40 % of subjects. A lactulose breath test for small intestinal bacterial overgrowth has been used to select patients who will respond. However, its predictive value, using the classic definition of a positive lactulose breath test, has been disappointing.

Aims

We conducted a retrospective evaluation to study characteristics of the lactulose breath test that may be predictive of a response to antibiotics in patients with the irritable bowel syndrome.

Methods

A clinical practice database was interrogated for consecutive patients who had a lactulose breath test for irritable bowel syndrome symptoms and a subsequent antibiotic course. Hydrogen + methane levels with carbon dioxide correction were plotted against time. Various profiles of the breath test curves were catalogued and compared with respect to their predictive value for symptom response to antibiotics.

Results

Lactulose breath test graphs of 561 patients of all irritable bowel syndrome subtypes were grouped into categories based on their hydrogen + methane levels with respect to time. Of subjects whose hydrogen + methane rise was <20 ppm throughout the test (group 1; N = 95), 94.7 % improved after antibiotics (95 % CI 90.1–99.3). Of those with a rise <20 ppm within the first 90 min but a rise >50 ppm thereafter (group 3; N = 53), 47.2 % improved (95 % CI 33.7–60.6). The difference between groups 1 and 3 was statistically significant P < 0.001.

Conclusion

A lactulose breath test appears to be useful in predicting response to antibiotics in patients with the irritable bowel syndrome. A hydrogen + methane rise <20 ppm throughout the duration of the test is most predictive. This observation contradicts the classic definition of a positive lactulose breath test.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.

    Article  CAS  PubMed  Google Scholar 

  2. Hwang L, Low K, Khoshini R, et al. Evaluating breath methane as a diagnostic test for constipation-predominant IBS. Dig Dis Sci. 2010;55:309–403.

    Article  Google Scholar 

  3. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009;18:349–358.

    Article  CAS  PubMed  Google Scholar 

  4. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24–33.

    Article  CAS  PubMed  Google Scholar 

  5. Posserud I, Stotzer P, Bjornsson E, Abrahamsson H, Simren M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802–808.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71.

    PubMed Central  PubMed  Google Scholar 

  7. Rana SV. Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Digestion. 2012;85:243–247.

    Article  CAS  PubMed  Google Scholar 

  8. Yu D, Cheeseman F, Vanner S. Combined oro-cecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-cecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2010;60:334–340.

    Article  PubMed  Google Scholar 

  9. Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol. 2008;103:958–963.

    Article  CAS  PubMed  Google Scholar 

  10. Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol. 2005;100:1566–1570.

    Article  CAS  PubMed  Google Scholar 

  11. Vanner S. The lactulose breath test for diagnosing SIBO in IBS patients: another nail in the coffin. Am J Gastroenterol. 2008;103:964–965.

    Article  CAS  PubMed  Google Scholar 

  12. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy. 2005;51:1–22.

    Article  CAS  PubMed  Google Scholar 

  13. Quigley, EMM. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol. 2014;30:141–146.

    Article  PubMed  Google Scholar 

  14. Saad RJ, Chey WD. Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy. Clin Gastroenterol Hepatol. 2014;12:1964–1972.

    Article  PubMed  Google Scholar 

  15. Lee KJ, Tack J. Altered intestinal microbiota in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:493–498.

    Article  CAS  PubMed  Google Scholar 

  16. Tack Jan. Antibiotic therapy for the irritable bowel syndrome. N Engl J Med. 2011;364:81–82.

    Article  CAS  PubMed  Google Scholar 

  17. Seyderhelm Richard. Die pathogenese der perniziösen anämie. Berlin Heidelberg: Springer; 1922.

    Book  Google Scholar 

  18. Löwenberg W. Über die Pathologische Bakterienansiedlung im Duodenum und Ihre Ursächlichen Faktoren. J Mol Med. 1926;5:548–551.

    Google Scholar 

  19. Esposito I, de Leone A, Di Gregorio G, et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol. 2007;13:6016–6021.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139–142.

    CAS  PubMed  Google Scholar 

  21. Pimentel M, Chow EJ, Lin HC. Eradication of Small Intestinal Bacterial overgrowth Reduces Symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–3506.

    Article  CAS  PubMed  Google Scholar 

  22. Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther. 2007;25:1271–1281.

  23. Esposito I, de Leone A, Di Gregorio G, et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol. 2007;13:6016–6021.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139–142.

    CAS  PubMed  Google Scholar 

  25. Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22:31–35.

    Article  CAS  PubMed  Google Scholar 

  26. Majewski M, Reddymasu SC, Sostarich S, Foran P, McCallum RW. Efficacy of rifaximin, a non-absorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci. 2007;333:266–270.

    Article  PubMed  Google Scholar 

Download references

Compliance with ethical standards

Conflict of interest

The study received no external funding and there are no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Connecticut Gastroenterology Institute, 39 Brewster Road, Bristol, CT, 06010, USA

    Rafid Kasir, Salam Zakko, Philip Zakko, Michael Adler, Aaron Lee, Sachin Dhingra & Cecile Guttermuth

Authors
  1. Rafid Kasir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salam Zakko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip Zakko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Adler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aaron Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sachin Dhingra
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cecile Guttermuth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Rafid Kasir or Salam Zakko.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kasir, R., Zakko, S., Zakko, P. et al. Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome. Dig Dis Sci 61, 846–851 (2016). https://doi.org/10.1007/s10620-015-3872-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-015-3872-9

Keywords

Search

Navigation